Diosmetin Maintains Barrier Integrity by Reducing the Expression of ABCG2 in Colonic Epithelial Cells
Authors:
- 3 June 2023
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 71 (23) , 8931-8940
Abstract
Crohn's disease (CD) is a relapsing and chronic inflammatory bowel disease. Recent advances have highlighted that dysfunction of the barrier function formed by a polarized monolayer of columnar epithelial cells plays a crucial role in the pathophysiology of CD. At present, we reported that diosmetin increased cell viability by reducing the levels of TNFα and IL-6 in lipopolysaccharide (LPS)-treated colonic epithelial Caco-2 cells. Meanwhile, diosmetin conferred a direct effect on maintaining barrier integrity by reducing epithelial permeability and increasing the expression of proteins associated with tight junctions, including zonula occludens-l (ZO-1), occludin, and claudin-1, in LPS-treated Caco-2 cells and in 2,4,6-trinitrobenzene sulfonic acid-induced CD mice. Additionally, diosmetin decreased the protein content of adenosine triphosphate-binding cassette efflux transporter G2 (ABCG2) in vitro and in vivo. Over-expression of ABCG2 had an important impact on the epithelial permeability and barrier-related protein levels induced by LPS in Caco-2 cells. At the same time, Ko143, a specific ABCG2 inhibitor, dramatically enhanced the role of diosmetin in ZO-1 and occludin proteins in LPS-treated Caco-2 cells. Mechanically, diosmetin significantly attenuated the role of LPS in the phosphorylation of adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK), phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB/AKT), and cAMP-response element binding protein (CREB) in Caco-2 cells. The AMPK inhibitor Compound C obviously prevented the effect of diosmetin on ZO-1 and occludin expression in LPS-treated Caco-2 cells. Taken together, the results of this study suggest that AMPK/AKT/CREB-mediated ABCG2 expression plays a crucial role in diosmetin, improving the barrier dysfunction in CD.Keywords
Funding Information
- Chongqing Municipal Education Commission (CYS21481, KJZD-K202101102)
This publication has 33 references indexed in Scilit:
- Intestinal Permeability in Inflammatory Bowel Disease: Pathogenesis, Clinical Evaluation, and Therapy of Leaky GutMediators of Inflammation, 2015
- Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2Proceedings of the National Academy of Sciences, 2013
- Geniposide Regulates Glucose-Stimulated Insulin Secretion Possibly through Controlling Glucose Metabolism in INS-1 CellsPLOS ONE, 2013
- A review on pharmacological and analytical aspects of diosmetin: A concise reportChinese Journal of Integrative Medicine, 2013
- Intestinal Permeability Defects: Is It Time to Treat?Clinical Gastroenterology and Hepatology, 2013
- Mucosal Barrier in Ulcerative Colitis and Crohn’s DiseaseGastroenterology Research and Practice, 2013
- Crohn's diseaseThe Lancet, 2012
- Intestinal Dendritic Cells and Epithelial Barrier Dysfunction in Crohnʼs DiseaseInflammatory Bowel Diseases, 2009
- Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's diseaseMucosal Immunology, 2008
- Inhibition of RICK/Nuclear Factor-κB and p38 Signaling Attenuates the Inflammatory Response in a Murine Model of Crohn DiseaseJournal of Biological Chemistry, 2005